[ad_1] Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense’s lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a safety and…
Tag: Endpoints
A note to our advertising partners: Endpoints News joins the Financial Times family
[ad_1] I’m thrilled to share with you the exciting news that Endpoints News is now officially a part of the Financial Times family. Today’s announcement is a wonderful testament to…